qavi project

INTEGRAL UNIVERSITY

Caring for life

“A Study of the Antibiotic with special reference to cipla”

Submitted In Partial Fulfilment for the Requirements For the Award of Master of Business Administration

Under the Guidance of: SUBMITTED BY Dr.M.S. KHAN ABDUL QAVI KHANHOD & DEAN FACULTY OF BUSSINESS MANAGEMENT M.B.A 3RD SEM

FACULTY OF BUSSINESS MANAGEMENT

INTEGRAL UNIVERSITY

LUCKNOW

Abdul Qavi khan Roll no-09001220021

INTEGRAL UNIVERSITY

FACULTY OF BUSINESS MANAGEMENT INTEGRAL UNIVERSITY

Dasauli, Kursi Road, Lucknow: 226026Phone: 0522-2890730 (Extn-2142)Web: www.integraluniversity.ac.in

CERTIFICATEThis is to certify that Mr. ABDUL QAVI KHAN, a student of MBA second year having

Roll No.0900122002 has completed his project Report on the subject Detail Study on “

“study of the Antibiotic with special reference to cipla”during

2010-2011 under my supervision and guidance.

The Project Report of the student is his own work and references have been duly

acknowledged.

I wish him all the best for his/her future.

(DR.M.S KHAN)DEAN & HOD FACULTY OF BUSSINESS MANAGEMENTINTEGRAL UNIVERSITY


INTEGRAL UNIVERSITY

ACKNOWLEDGEMENT

Accomplishment of tasks and objective is achieved by guidance and blessings of

elders, teachers, nears and dears and of course by the grace of Almighty. It is a great

opportunity for me to register my acknowledgements to all of them.

It has been a profound privilege for me to have an opportunity to work under DR.

M. S. Khan Head, Faculty of Business Management.

I wish to acknowledge my deep sense of gratitude to my guide in cipla Mr. Abhishek

sukla&faulty of MBA Department for accomplishment of this project report as well as

for every sphere pertaining to successful occupation of this course.

Finally, I pay my regards to all, who directly or indirectly helped in collection,

compilation, editing and other related works for accomplishment of this project

study.

At last, I also thank the employees of cipla assisting me in the timely completion of project.

(ABDUL QAVI KHAN)


INTEGRAL UNIVERSITY

PREFACE

Marketing Research plays a key role in entire marketing process. It helps the firm

in market measurement, assessment of market, potential development of sales forecast,

product assessment and about competitors and so on. It also helps the firm to acquire a

better understanding of consumers and marketing environment. It aids the formulation of

Product Mix.

As a matter of fact decision making of each element of the marketing like Product

and Service Mix, Distribution Mix and Pricing Policy relies heavily on Marketing

Research. These days there is a cut throat competition in the market. The same is the case

in Pharmaceutical Industry. The market is flooded with many brand of Antibiotic with

different pricing, and Marketing Strategy.

So the condition of the market is "Survival of Fitness" and if a firm wants to

survive it will have to make effort to known the Consumer/Doctor's needed, his

preference change in Market Environment etc. and the Marketing Research is the best

way to do it.


INTEGRAL UNIVERSITY

So I am doing my Project on "Market Share of Antibiotic in Lucknow Area" for

Cipla Pvt. Limited.

There are five Antibiotics which are covered in study, are:-

Ceftriaxone Pluse Taxobactum.

Emeset

Biozova (Pre & Probiotic)

Nitazid (Nitazoxauide)

Predone (Prednisolone)

For data collection I visited maximum Pediatrician and Chemist in all area of

Lucknow City. This is minimum humble effort towards the project.


INTEGRAL UNIVERSITY

HISTORY OF CIPLA PHARMACEUTICAL COMPANY

Khwaja Abdul Hamid, the founder of Cipla, was born on October 31, 19898. The

fire of nationalism was kindled in him when he was 15 as he witnessed a wanton act of

colonial highhandedness. The fire was to blaze within him right through his life.

In college, he found Chemistry fascinating. He set sail for Europe in 1924 and got

admission in Berlin University as a research student of "The Technology of Barium

Compounds". He earned his doctorate there years later.

In October 1927, during the long voyage from Europe to India, he drew up great

plans for the future. He wrote : "No modern industry could have been possible without

the help of such centres of research work where men are engaged in compelling nature to

yield her secrets to the ruthless search of an investigating chemist. "His plan found many


INTEGRAL UNIVERSITY supporters but no financiers. However, Dr. Hamied was determined to being "a small

wheel, no matter how small, than be a cog in a big wheel".

In 1935, he set up The Chemical, Industrial & Pharmaceutical Laboratories,

which came to be popularly known as Cipla. He gave the company all his patent and

proprietary formulas for several drugs and medicines, without charging any royalty. On

August 17, 1935, Cipla was registered as a public limited company with an authorized

capital of Rs. 6 Lakhs.

Cipla was officially opened on September 22, 1937 when the first products were

ready for the market. The Sunday Standard wrote : "The birth of Cipla which was

launched into the world by Dr. K.A. Hamied will be a red letter day in the annals of

Bombay Industries. The first city in India can now boast of a concern, which will

supersede all existing firms in the magnitude of its operations. India has lagged behind in

the march of science but she is now awakening from her lethargy.


INTEGRAL UNIVERSITY

MAHATMA GANDHI VISIT CIPLA

July 4, 1939 was a red-letter day for Cipla, when the Father of the National, Mahatma

Gandhi, honoured the factory with a visit. He was "delighted to visit this Indian

enterprise", he noted latter. From the time Cipla came to the aid of the nation gasping for

essential medicines during the Second World War, the company has been among the

leaders in the pharmaceutical industry in India.


INTEGRAL UNIVERSITY

MAHATMA GANDHI VISITS CIPLA

On October 31, 1939, the books showed an all time high loss of Rs. 67,935. That

was the last time the company every recorded a deficit.

In 1942, Dr. Hamied's blueprint for a technical industrial research institute was

accepted by the Government and led to the birth of the Council of Scientific and

Industrial Research (CSIR), which is today the apex research body in the country :

In 1944, the company bought the premises at Bombay Central and decided to put

up a "first class modern pharmaceutical works and laboratory". It was also decided to

acquire land and buildings at Vikhoroli. With severe import restrictions hampering

production, the company decided to commence manufacturing the basic chemicals

required for pharmaceuticals. In 1946, Cipla's product for hypertension, Serpinoid, was

exported to the American Roland Corporation, to the tune of Rs. 8 Lakhs. Five years

later, the company entered into an agreement with a Swiss firm for manufacturing

foromycene.

Dr. Yusuf Hamied, the founder's son, returned with a doctorate in chemistry from

Cambridge and joined Cipla as an officer in charge of research and development in 1960.


INTEGRAL UNIVERSITY In 1961, the Vikhroli factory started manufacturing diosgenin. This heralded the

manufacture of several steroids and hormones derived from diosgenin.


INTEGRAL UNIVERSITY

Business Standard, Mumbai Friday, December 09, 2005"We have no intentions of selling Cipla"

Q&A: Yusuf K Hamied

Yusuf K Hamied, Chairman and Managing Director, Cipla wants to put an end to

rumours that multinational giants are in talks with the pharma company to acquire it. In

an interview with Business Standard, Hamied emphasizes the importance of international

collaborations and partnerships for Indian pharma companies to grow in the global

market space, but insists that Cipla's dealings with multinational companies has so far not

gone beyond such collaborations. Excerpts :

There are strong rumours that multinational pharma firms are in talks with Cipla for a

complete acquisition. Even names like Teva, Pfizer, Sandoz and Ranbaxy were making

the rounds. Is there any basis for such rumours?

As matters stand today, we have no intention of selling the company. These all are quite

speculative and have no substance. I have not been talking to any of these companies and

I'm sure, it will not happen in my life time. At the same time, national as well as

international business collaborations are crucial for Indian pharma companies to sustain

growth in the domestic and global market space. However, we cannot predict the future

situation at this point of time. Though our company had alliances with both these entities,


INTEGRAL UNIVERSITY the acquisition deal and the consolidation process between these two have not made any

impact on Cipla yet.

Cipla made successful moves to lower the prices of HIV/AIDS drugs globally by

introducing cheaper generics despite pressure from multinationals. There has been

criticism that the company will capture a sizeable market for its generic drugs in those

markets. How do you respond to this?

Cipla's move has been a part of its commitment to the population of India and it is the

same with any other poor country which cannot afford the high drug prices fixed by

multinationals, who enjoy a monopoly in the name of patent protection. In India,

healthcare is in a state of perpetual crisis as the disease profile is frightening here. Same

is the case with many of the poor countries. It was a hold step on our part to announce a

major price reduction for our triple drug cocktail Triomune – at below SI per patient.

However, the multinationals are now on the defensive. Apart form lowering their prices,

they accused us of not having WHO approval for our anti-AIDS drugs.

Do you support the intellectual property Rights (IRP) regime in India?

We respect patents. But is should not lead to a monopoly as the country cannot afford to

have such a situation, at least in the case of medicines. What we want is a permanent

compulsory licensing system to ward off monopoly. This will allow generic drug


INTEGRAL UNIVERSITY companies to produce the drug by paying a royalty, for the benefit of the large majority

of the Indian population. Cipla believes in that and it is ready to pay 4 percent royalty to

the originator. The bird flu threat has; in fact, given the country an opportunity to take

hard look on how it wants to implement the product patent regime that has now became

effective here.

When Novartis was granted the exclusive marketing right (EMR) for its anticancer drug

Glivac, despite the lack of clarity on the claims of the originator, generic companies,

including Cipla, had to withdraw their generics from the patents are granted on such

borderline cases?

Imatinib was apparently a borderline case. So the government should not have granted

the EMR. As the drug had a patent granted per-1995, it don’t deserved the grant of patent

in India as per the current IPR law. Following the exclusive marketing right (EMR)

granted to Novartis, the generic players had to withdraw their cheaper versions, leaving

thousands of poor patients in the lurch. It should not happen. Using the opportunities such

as pre-and even post-grant oppositions, generic companies should come forward to

prevent such non-deserving candidates from obtaining patent protection, for safeguarding

public health.

What are you growth strategies for Cipla, including future investments?


INTEGRAL UNIVERSITY The company has plans to invest about Rs. 300 crore towards capacity expansion at all its

facilities in Baddi, Patalganga, Kurkumbh and so on. The facilities will be upgraded in

view of the stringent requirements of the global market. The company expected to clock a

15-percent growth in sales in the financial year 2006. Profits will be in line with the

previous year. Exports will be a thrust area for Cipla in future. We currently spend about

4 percent of our turnover on research and development and it will go up significantly in

the coming years.

When Novartis was granted the exclusive marketing right (EMR) for its

anti-cancer drug Glivac, despite the lack of clarity on the claims of the

originator, generic companies, including Cipla, had to withdraw their

generics from the market. Do you foresee the same kind of situation in

the post-IPR regime when patents are granted on such borderline

cases?

Imatinib was apparently a borderline case. So the government should not have granted

the EMR. As the drug had a patent granted pre-1995, it didn’t deserved the grant of

patent in India as per the current IRP law. Following the exclusive marketing right

(EMR) granted to Novartis, the generic players had to withdraw their cheaper versions,

leaving thousands of poor patients in the lurch. It should not happen. Using the

opportunities such as pre-and even post-grant oppositions, generic companies should


INTEGRAL UNIVERSITY come forward to prevent such non-deserving candidates from obtaining patent protection,

for safeguarding public health.

CIPLA PRODUCTS

OLMECIP – The Sartan with Double Digit Advantage

Despite the increasing number of antihypertensive medications, epidemiological data

have shown that fewer that one-third of hypertensive patients achieve BP goal of <

140/90 mm Hg. Hence, 90 out of 100 patients with hypertension may have inadequately

controlled blood pressure. Thus there is a need for more potent and effective agents to

control hypertension.

Amongst the various causes of hypertension, the rennin-angiotensin system (RAS) is a

major determinant of blood pressure and intravascular volume.

OLMECIP (Olmesartan medoximil) is a new potent agent that acts on RAS by preventing

the vasoconstrictor effects of angiotensin II by selectively blocking the binding of

angiotensin II to the AT 1 receptor in the vascular smooth muscle. Its action is, therefore,

independent of the pathways for ongiotensin II synthesis. It shows, 'insurmountable'

binding profile with more than a 12500-fold greater affinity for the AT 1 receptor than

for the AT 2 receptor.


INTEGRAL UNIVERSITY OLMECIP shows powerful effects on blood pressure (BP) causing double-digit blood

pressure reduction. It has a prolonged terminal elimination half-life of 12-18 hours, which

is longer that most other AT 1 receptor antagonist. This favorable pharmacokinetic

profile, coupled with its 'insurmountable' receptor binding, allows the drug to be

administered on a once-daily basis.

Further, OLMECIP has a consistent 24-hour BP control which is clinically important in

controlling the early morning surge in BP that appears to contribute to an increased risk

of cardiovascular events during that time.

The antihypertensive effect of OLMECIP is seen within 1 week of treatment initiation

with near-maximal effects being seen at 2 weeks. This offers the opportunity to achieve

early BP control without the need for prolonged dose-titration schedules.

INDICATION

OLMECIP is indicated for the treatment of hypertension. It may be used alone or in

combination with other antihypertensive agents.

DOSAGE AND ADMINISTRATION

The usual recommended starting dose of OLMECIP is 20 mg once daily when used as

monotherapy in patients who are not volume-contracted. For patients requiring further

reduction in blood pressure after 2 weeks of therapy, the dose of OLMECIP may be


INTEGRAL UNIVERSITY increased to 40 mg. Doses above 40 mg do not appear to have greater effect. Twice-daily

dosing offers no advantage over the same total dose given once daily.

STRENGTHS AVAILABLE :

OLMECIP 20

Olmesartan medoxomil 20 mg tablets

OLMECIP 40

Olimesartan medoxomil 40 mg tables

RID-AR : TOWARDS BETTER MANAGEMENT

Rid-AR is a combination of an antileukotriene montelukast and an antihistamine like

levocetirizine. Since histamine produces the initial manifestations of alleric rhinitis (AR)

such as sneezing, nasal itching etc. and leukotrienes are involved in both early and late

phase reactions (persistence of symptoms, nasal congestion) thus combing these two

classes of drugs could produce greater and more complete control of symptoms and the

disease. Several studies have been conducted of such a combination, which lead credence

to this hypothesis. Potentially, such a combination could be as effective as intranasal

corticosteroids, which are the only class of drugs, which control most symptoms of AR.

Rid-AR is indicated in the treatment and/or prevention of symptoms of allergic rhinitis. It

can be used in both seasonal and perennial allergic rhinitis particularly in mild persistent


INTEGRAL UNIVERSITY cases as monotherapy, as initial therapy in moderate-to-severe intermittent rhinitis and as

initial suffering from concomitant asthma and alleric rhinitis. Rid-AR is recommended as

prophylaxis in prevention of allergic rhinitis.

Rid-AR is recommended in form of a once daily dose of montelukast 10 mg and

levocetirizine 5 mg in adults 15 years and above.

The New Baby Mast is designed to make administration of the inhaled bronchodialators

& anti-inflammatory drugs to the lungs through the metered does inhaler & Zerostat-V

Spacer easier to infants & children below 3 years.

With the help of the new BabyMask a child can easily inhale the medicine, while

breathing in & out through the mouth normally. New BabyMask has following added

features :

Shape: Provides better seal & more comfort to the child.

Design: Snugfit with Zerostat, Zerostat – V spacers.

Exhalation vent helps in easy breathing.


INTEGRAL UNIVERSITY

SIMPLYONE – ASTHMA CONTROL SIMPLIFIED AND PERSONALIZED

Simplyone combining a novel inhaled corticosteroid (ICS) – 'Ciclesonide' and best long-

acing beta 2-against (LABA) – 'Formoterol' represents a significant advancement for

management of patients with asthma. Simplyone combines the safety and efficacy of

ciclesonide with the unique bronchodilatory properties of formoterol Simplyone –

Highlights

Rapid onset of action providing quick relief due to formoterol.

Enhanced Safety Profile – High margin of safety for ciclesonide – the ideal

corticosteroid with substantially reduced risk for both oropharyngeal and systemic

side Safest (ICS + LABA) combination especially in patients requiring higher

doses of inhaled steroids to control their asthama, without the associated concerns

regarding side-effects.

Longer Duration of Action – The dosage can be tapered to once daily therapy

after control is achieved with initial twice daily treatment.

The benefits obtained with formoterol/budesonide combination when used as

maintenance as well as reliever therapy, approved by GINA 2006, may even be

extended to this new combination – Simplyone.

Simplified asthma therapy – Thus improving adherence and better disease control.


INTEGRAL UNIVERSITY

Simplyone is indicated in the regular treatment of asthma, where use of a combination

(long acting beta 2-against and inhaled corticosteroid) has been found to be appropriate.

Dosage and Administration

Asthma

Adutls and Adolescents (12 years and older)

Simplyone 80/160 Inhaler

1 to 2 inhalations twice daily

Simplyone 200 Rotacaps

1 to 2 Rotacaps twice daily


1 Rotacap twice daily

The maximum recommended dose for ciclesonide is 640 mcg (MDI) and 800 mcg (DPI).

The dose of Simplyone is individual and adjusted according to disease severity. When

control has been achieved, the dose should be titrated to the lowest effective dose, which

could include Simplyone given once daily.


INTEGRAL UNIVERSITY

CIPLA LAUNCHES ANTIFLU

Cipla has successfully launched a generic version of the bird flue drug-Oseltamivir. Cipla

has received marketing approval from the Drug Controller General of India to market this

drug in the domestic market. Cipla plans to market the product in various countries.

The Hindu Business Line, New Delhi, Friday, 17 th February 2006

Clinton to Visit Cipla Goa Unit

P.T. Jyothi Datta

Indian companies manufacturing AIDS drugs will see increased activity this week. While

the former US President, Bill Clinton, is scheduled to visit Cipla's Goa plant later this

week, Bristol Myers Squibb (BMS) has announced a global AIDS-drug related

technology-transfer deal with Pune-manufacturer.

Cipla's Joint Managing Director, Amar Lulla, confirmed that Clinton would be visiting

Cipla's Goa plant on Saturday. Cipla was already supplying antiretroviral drug (AIDS

medicines) in both the adult and paediatric versions to the Clinton Foundation, he said.

The forthcoming visit may help reinforce the existing deal and scale it up, he indicated.

In another significant development overseas, BMS has inked an agreement for

technology transfer, where there will be a royalty-free licence on the AIDS drug


INTEGRAL UNIVERSITY Atazanavir to Emcure and Aspen. Atazanavir, sold by BMS under the brand name

Reyataz, is a once-a-day protease inhibitor for AIDS drugs that was approved in the US

in mid-2003.

Peak Flow Mater

Peak Flow Master, is a simple, portable device that measures air flow or peak expiratory

flow rate (PEFR).

It is important aid in the diagnosis and subsequent treatment of asthma.

Peak Flow Mater is ideal for in-clinic use by doctors, and all those patients for

whom day-to-day objective monitoring is recommended by their doctors.

Peak Flow Master has a new log-linear scale and conforms with the recent EN 13826 :

2003 standards approved by the European Union (EU).

Colette – Corrects prolactin, Balances life.

Colette contains c abergoline, a dopamine receptor agonist, for oral administration,

available as Collette 0.5 mg and Colette 0.25 mg.

Hyperprolactinemia

This is an excessive production of proplactin in a non-pregnant woman or in males.

Hyperprolactinemia can cause a variety of reproductive problems; including irregular or

absent menstrual cycles and inadequate production of progesterone during the luteal

phase of the cycle in females. Galactorrhoea is a common side affect of


INTEGRAL UNIVERSITY hyperprolactinemia. This is an excessive production of milk (in non-pregnant women),

which can be secreted from the nipple by itself or with gentle expression of the nipple. In

males, loss of libido, impotency or infertility is generally seen.

Treatment option are a) Medications such as cabergoline or bromocsriptine – work by

suppressing the production of prolactin, b) Surgery and c) r adiation are reserved for

resistant or intolerant cases.

Location

It means secretion of milk from the mammary glands to provide milk to the new born.

Location does not occur during pregnancy because estrogen & progesterone oppose the

effects of prolactin on mammary tissue. After delivery, there is a sudden fall in estrogen

and progesterone level, allowing location to begin. But in some conditions it may be not

possible to breast-feed the child due to conditions like Stillbirth, Adoption, Infant in ICU,

Working mother or Medical contraindications or infant diseases such as cleft lip & palate.

In such cases inhibition of puerperal lactation may be required.

Cabergoline

Cabergoline is a dopamine receptor agonist with a high affinity for D 2 receptors and

exerts a direct inhibitory effect on the secretion of prolactin by pituitary lactorophs.

Colette is indicated in

Hyperprolactinemia

Inhibition of lactation


INTEGRAL UNIVERSITY Suppression of lactation

The dosage in Hyperprolactinemia

Initiation of therapy – 0.5 mg/week – single / 2 divided doses (0.25 mg) twice/wk.

Weekly dose – Increased by adding 0.5 mg/week at monthly intervals till an

optimal therapeutic response.

Monitoring of serum prolactin levels at monthly interval is recommended till

normoprolactinemia or maximum therapeutic response is achieved.

The dosage for Inhibition/suppression of physiological lactation Colette is indicated for

the inhibition of physiological lactation soon after delivery and for suppression of already

established lactation.

For inhibition of lactation cabergoline should be administered during the first day

postpartum. The recommended therapeutic dose is 1 mg given as a single dose.

For suppression of established lactation the recommended therapeutic dose regimen is

0.25 mg every 12 hours for two days (total dose of 1 mg).

Cabergoline should preferably be taken with food for all therapeutic indications.


INTEGRAL UNIVERSITY Colette is contraindicated in uncontrolled hypertension, known hypersensitivity to ergot

derivatives and women with a history of puerperal psychosis.


INTEGRAL UNIVERSITY

Cresar : See the Complete Picture

Cresar (Telmisartan) is an angiotensin type 1 (AT 1) receptor blocker mainly indicated

for the management of hypertension.

Telmisartan is an ARB with dual function i.e. it inhibits AT 1 receptor and acts as a

partial agonist of peroxisome has the longest elimination half life as compared to all other

ARBs, leading to sustained duration of actio particularly at the end of the dosing interval

as compared to losartan. Telmisartan once daily elicits a smooth, consistent, clinically

relevant reduction in BP throughout a 24-hour period.

In hypertension, telmisartan is superior to losartan, valsartan and ramipril in reducing the

24-hour ambulatory BP as well as the BP in the last 6 hours of dosing interval.

Telmisartan is also at least as effective as other classes of antihypertensive drugs like

calcium channel blockers, beta-blockers and ACE inhibitors. Telmisartan effectively

reduces BP and proteinuria in patients with nephropathy in moderate or severe stages of

renal insufficiency. Also, telmisartan offers renoprotection that is clinically equivalent to

enalapril in patients at high risk for cardiovascular events. As a result of its PPAR g

activation, telmisartan improves insulin sensitivity, reduces lipids and exerts

antiatherosclerotic benefits.


INTEGRAL UNIVERSITY In diabetic hypertensives, telmisartan significantly improved plasma lipids, decreased

fasting insulin levels, fasting plasma glucose and HBA 1 levels. Serum adiponectin levels

were significantly increased and CRP levels were decreased with telmistartan.

Telmisartan exhibits placebo-like tolerability. The incidence of cough with telmisartan is

significantly less than that seen with lisinopril and comparable to placebo. The adverse

experiences have generally been mild and transient.

The usual starting dose is 40 mg once daily. Some patients may derive benefit with 20

mg. Most of the antihypertensive effect is apparent within two weeks and maximal

reduction is generally attained after four weeks. When additional BP reduction beyond

that achieved with 80 mg telmisartan is required, diuretic may be added. In patients with

severe renal impairment or haemodialysis, a lower starting dose of 20 mg is

recommended. In patients with mild to moderate hepatic impairment, dosage should not

exceed 40 mg once daily.


INTEGRAL UNIVERSITY

Cresar – H : Harmony of Dual Sartan With Diuretic

Cresar – H is a fixed dose combination of telmisartan (angiotensin receptor blocker) and

hydrochlorothiazide (thiazide diuretic). This fixed-dose combination provides a balanced

and synergistic antihypertensive effect in controlling blood pressure in hypertension

along with a significant regression of left ventricular hypertrophy. Also, this combination

is efficacious in a wide range of patient population – young as well as the elderly and in

patients with low as well as high levels of rennin.

The efficacy of Cresar – H combination has been well established over the monotherapy,

as compared to losartan/HCTZ & enalapril / HCTZ.

The combination of telmisartan-hydrocholorothiazide is well tolerated and the efficacy is

maintained over 3 years. Cresar-H exhibits an improved safety profile, whereby

hypokalemia associated with hydrocholorothiazide is attenuated by coadministration of

telmisartan. Cresar-H improves patient compliance.

The usual initial, dosage is one tablet of Cresar-H daily. The dose may be increased, if

necessary, to two tablets of Cresar-H daily. In patients with renal impairment, the usual

dose is followed as long as the patient's creatinine clearance is > 30 ml/min. In patients


INTEGRAL UNIVERSITY with more severe renal impairment, Cresar-H is not recommended. In p atients with

hepatic impairment, Cresar-H is not recommended for patients with severe hepatic

impairment. Patients with biliary obstructive disorders or hepatic insufficiency should

have treatment started under close medical supervision.

Cresar-H is available as Cresar-H tablets (Telmisartan 40 mg + Hydrocholorothiazide

12.5mg).


INTEGRAL UNIVERSITY

IF2 Eye Drops – The New Age Anti – Allergic

Olopatadine hydrochloride 0.1% w/v eye drops

IF2 eye drops for Itch Free Eyes: Twice daily convenience with a dual mechanism of

action.

Olopatadine Demonstrates Mast cell stabilizing activity

It is the first topical ophthalmic anti-allergy agent that has clinically shown mast-cell

stabilization in human eyes.

Inhibits 96% of histamine release from conjunctival mast cells in vitro Olopatadien

decreases adhesion molecule expression results in decreased leukocyte infiltration and

prevention of other events which lead to inflammatory process associated with allergy

Olopatadine : Antihistaminic agent

Olopatadine is a potent antihistamine with high affinity for H1 receptors and some

affinity for H2 receptors.

Effectively block the action of histamine on various sites namely

1. Nerve endings thus relieves the eyes from ocular itch

2. Blood vessel walls thus reducing chemosis

3. Eyelids thereby decreasing lid edema


INTEGRAL UNIVERSITY Indications

Olopatadine hydrochloride ophthalmic solution is indicated for the treatment of the signs

and symptoms of allergic conjunctivitis.


The recommended dose of olopatadine is one drop in each affected eye two times per day

at an interval of 6 to 8 hours.

Highlights

Potent mast cell stabilizing ability : Olopatadine is the first topical ophthalmic anti-

allergy agent that has clinically shown mast-cell stabilization in human eyes.

Fast Acting : Olopatadien reduces itching within 3 minutes of administration to the

eyes.

Long lasting relief : Dual mechanism of action of olopatadine gives an immediate and

a long lasting relief for upto 8 hrs.

Superior Efficacy : Olopatadien is 43% more effective than Ketotifen, 37% more

effective than Azelastine.


INTEGRAL UNIVERSITY

Latim – One Drop. Drops IOP Better

(Latanoprost 0.005% + Timolol Maleate 0.5%)

Latim (LTFC) is a combination of Timolol maleate 0.5% a ( blocker) and Latanoprost

0.005% (a prostaglandin analogue). The two components work together to result into an

additive IOP lowering effect than the two components administrated individually.

The rationale for the fixed dose combination of Latanorprost, an outflow facilitator and

Timolol, an aqueous suppressor is based on the complementary mechanism of action and

efficacy of the two components. Thus combining the benchmark topical blocker

(Timolol) and the prostaglandin analogue Latanoprost confers a superior efficacy on

LTFC.

Amongst a number of combination therapies, which have been studied, Latanoprost-

timolol fixed combination (LTFC) is observed to lower the IOP by 49% post single dose

Latim not only brings about a powerful reduction in IOP, but with a easy once daily

dosing regimen, it also increases patient compliance, convenience and therapeutic

efficacy.

Latim Offers

Improved diurnal IOP control

13-36% additional IOP reductions with LTFC as compared to those on

monotherapy.

Efficacy maintained over a period of 12 months.


INTEGRAL UNIVERSITY Latim is indicated for the reduction of intraocular pressure (IOP) in patients with open

angle glaucoma and ocular hypertension who are not controlled on, or are intolerant to,

monotherapy with compounds other than latanoprost and timolol.

The recommended dosage is one drop in the affected eye(s) once daily.


INTEGRAL UNIVERSITY

Antiflu

The recent transmission of the highly pathogenic H5N1 avian influenza virus strain to

human has highlighted the threat of pandemic influenza.

Oseltamivir (Antiflu) has proven to be safe and effective for the prevention of treatment

of all known influenza subtypes, reducing the severity and duration of symptoms, the

complications arising from influenza infection (pneumonia, hospitalization, antibiotic

use) and mortality. Oseltamvir (Antiflu) in vitro studies has been shown to be effective

against pandemic strains of influenza, including the currently circulating strain (H5N1).

The recommended dose of Antiflu for the treatment of influenza, in adults and

adolescents 13 years of age and older, is 150 mg per day, given as 75 mg twice a day for

five days. The recommended oral dose of Antiflu for prophylaxis of influenza in adults

and adolescents 13 years and older following close contact with an infected individual is

75 mg once daily for at least 10 days. Safety and efficacy have been demonstrated for

upto 6 weeks. In patients with H5N1 infection (avian influenza), WHO recommends

higher doses than standard of oseltamivir (keeping in mind that 300 mg/day is associated

with higher side effects) for a longer duration (7-10 days).

Administration of the drug should also be considered in patients presenting later in the

course of the disease.


INTEGRAL UNIVERSITY Longer Duration of Action – The dosage can be tapered to once daily therapy

after control is achieved with initial twice daily treatment.

The benefits obtained with formoterol/budesonide combination when used as

maintenance as well as reliever therapy, approved by GINA 2006, may even be

extended to this new combination – Simplyone.

Simplified asthma therapy – Thus improving adherence and better disease control.

Simplyone is indicated in the regular treatment of asthma, where use of a combination

(long acting beta-2 agonist and inhaled corticosteroid) has been found to be appropriate.

Dosage And Administration

Asthma

Adults and Adolescents (12 years and older)

Simplyone 80/160 Inhaler

1 to 2 inhalations twice daily


1 to 2 Rotacaps twice daily


1 Rotacap twice daily

The maximum recommended dose for ciclesonide is 640 mcg (MDI) and 800 mcg (DPI).

The dose of Simplyone is individual and adjusted according to disease severity. When


INTEGRAL UNIVERSITY control has been achieved, the dose should be titrated to the lowest effective dose, which

could include Simplyone given once daily.


INTEGRAL UNIVERSITY

Neosurf : Gives Life a Second Breath

Premature neonates who have not manufactured adequate amounts of surfactant suffer

from neonatal respiratory distress syndrome (NRDS), wherein the lungs collapse at the

end of exhalation. The damage done to lung tissues by the cycles of collapse and re-

inflation causes respiratory failure. Treatment of these infants with externally applied

prophylactically around the time of their first breath, and also those who have already

developed NRDS before receiving the treatment. Surfactant is necessary for normal

respiratory function. Surfactant prevents atelecatasis and oedema, because of low

interfacial surface tension. It maintains gas exchange and decrease the work of breathing.

Furthermore, surfactant serves as a lubricant protecting the airways and promoting

mucociliary transport.

The need for supplementary oxygen and mechanical ventilation decreases in patients

receiving surfactant. The incidence of pneumothorax and interstitial emphysema is

decreased by 50 to 80% with surfactant therapy Analysis of all randomized trials

indicates that surfactant supplementation decreases neonatal mortality by about 33% and

increases survival without chronic lung disease by about 17% Neosurf is a new natural

surfactant developed in Canada. It is lipid extract in patients administered Neosurf have

demonstrated rapid improvements in oxygenation and reduction of supplementary


INTEGRAL UNIVERSITY oxygen and mechanical ventilation. Compared to currently available surfactants, Neosurf

has advantages in terms of rapid onset of action and the quality of surfactant.

Neosurf in intended for INTRATRACHEAL instillation only after an endotracheal

airway has been established.

The recommended dosage of Neosurf is 5 ml/kg. at 27 mg of phospholipids/ml, which

equals 135 mg phospholipids/kg. As many as three subsequent dose of Neosurf can be

given within the first 5 days of life.


INTEGRAL UNIVERSITY

Nadibact: Face to face with life

Nadibact cream contains nadifloxacin, the only fluroquinolone for topical use. It inhibits

the enzyme DNA gyrase, which is involved in bacterial DNA synthesis and replication,

thus inhibiting the bacterial multiplication. It has got potent bactericidal activity and

additional ani- inflammatory property.

In vitro studies of nadifloxacin showed a potent and broad spectrum antibacterial activity

against aerobic Gram- positive, Gram- negative and anaerobic bacteria, including

Propionibacterium acnes and Staphylococcus epidermidis. Nadifloxacin showed potent

antibacterial activity against methicillinresistant Staphylococcus aureus (MRSA), which

was similar to potency against methicillin- sensitive Staphylococcus aureus (MSSA). The

drug was also active against new quinolone resistant MRSA. Nadifloxacin doses not

show cross resistance with other new quinolones.

Nadibact cream is indicated for treatment of acne vulgaris andsuperficial bacterial

infections of skin. It should be applied to the lesions twice daily. In case of acne, it should

be applied after washing the face. With Nadibact cream mild and transient side effects

like itching, erythema and swelling may occur at the site of application.


INTEGRAL UNIVERSITY

Dytor Plus: The Next Upgrade in Edema Control

Dytor Plus is a Fixed- dose combination of torsemide and spironolactone, launched for

the first time in the world. It is indicated for the relief of edema associated with

secondary hyperaldosteronism in liver cirrhosis, congestive heart failure and syndrome. It

is also indicated in hypertension with hyperaldosteronism.

Torsemide is a powerful loop diuretic that blocks the Na+ /K + /Cl- transporter in the

loop of Henle and exhibits various advantages over frusemide viz. greater potency, longer

duration of action, more complete and predictable bioavailability, lesser kaliuresis and no

risk of drug accumulation.

Spironolactone is a potassium sparing diuretic and specific aldosterone antagonist, which

competitively binds to receptors at the aldosterone- dependent sodium- potassium

exchange site in the distal convoluted renal tubule of the nephron. It causes diuresis and

natriuresis, whole retaining potassium.

In liver cirrhosis, torsemide plus spironolactone causes significantly greater diuresis,

natriuresis and free water clearance, with lesser patients requiring upward dose titration

as compared to frusemide plus spironolactone combination. It has also been showm

reduction in body weight, ascites, edema, abdominal firth and ankle circumference. In

CHF, torsemide plus spironolactone combination may provide significant reduction in

mortality and hospitalization rates and increased efficacy in relieving edema. Studies


INTEGRAL UNIVERSITY have shown that both torsemide and spironolactone reduce myocardial fibrosis and left

ventricular remodeling in CHF. Torsemide and spironolactone combination can also help

to tackle diuretic resistance as this combination results in dual blockade of the nephron at

the loop of Henle as well as at the distal convoluted tubule and achieve edema relief. In

nephritic syndrome, torsemide in combination with spironolactone significantly reduced

body weight, proteinuria by almost 50% and relieved peripheral edema. When

spironolactone therapy is combined with torsemide, the hyperkalemia and

hypermagnesemia caused by spironolactone can be attenuated by the hypokalemia and

hypomagnesemia caused by torsemide, respectively and vice versa

Dytor Plus is available in two strengths: Dytor Plus 10 (torsemide 10 mg +

spironolactone 50 mg) and Dytor Plus 20 (torsemide 20 mg + spironolactone 50 mg).

Dosage must be individualized. The recommended usual initial dose 1 to 2 tablets of

Dytor Plus 10.


INTEGRAL UNIVERSITY

Propcaine-Promises Quality, Promises Success

Proparacaine hydrochloride 0.5% Eye drops

Proparacaine 0.5% - The only topical anaesthetic approved for ocular administration by

U.S. FDA

Propcaine contains proparacaine, which is an ester type of specific surface acting local

anaesthetic available in a 0.5% w/v.

After topical application to the eye, proparacaine penetrates to sensory nerve endings in

the corneal tissue. It blocks both the initiation and conduction f nerve impulses thereby

causing anaesthesia.

Proparacaine eye drops provides complete analgesia during surgery, wears off rapidly

following surgery and does not interfere with the patient's ability to blink, or move the

eye.

Propcaine: Highlights

Rapid onset of action

Relatively short duration

No Mydriasis

No IOP change

Minimal pain on instillation

No cross allergy with tetracaine


INTEGRAL UNIVERSITY Repeated applications can be used during intraocular surgery/ operations

Fever allergic reactions as compared to other topical ocular anaesthetics

Indications

Proparacaine ophthalmic solution is indicated for the following procedures:

Corneal anaesthesia of short duration e.g. Tonometry, Gonioscopy,

Removal of corneal foreign bodies and for short corneal and conjunctival

procedures.


For removal of foreign bodies and sutures and for tonometry:

1-2 drops (in single instillations) in each eye before operating.

1) Tugain 2% & Tugain 5%: More Hair Per Care

Tugain contains minoxidil with hydrolyzed keratin. When applied topically minoxidil

stimulates hair growth in persons with male pattern baldness.

Hydrolyzed keratin penetrates into the cortex, strengthens the hair shaft and mena

split ends. It creates a protein shield on the surface of the hair to protect from

excessive environmental damage and helps to maintain youthful state of the hair.

Hydrolyzed keratin provides an uniform cuticle smoothing effect on hair fibers, thus

enhances gloss and smoothness.

Tugain 2% is indicated for the treatment of androgenic alopecia in men (male pattern

baldness) and women (female pattern baldness).

Tugain 5% is indicated for the treatment of andrognic alopecia only in men 1 ml of

Tugain 2% and Tugain 5% should be applied twice daily at 12 hours interval to the


INTEGRAL UNIVERSITY scalp, beginning at the center of the affected area and spread to cover the entire

affected area. Apply Tugain when hair and scalp are clean and dry Total daily dose

should not exceed 2 ml. The drug should not be massaged into the scalp and it should

be applied lightly. Hair dryer should not be used to speed the drying of Tugain

solution as it may decrease the effectiveness. Tugain should not be mixed with any

hair oil. It should not be applied to any other parts of the body. Hands should be

washed thoroughly after applying Clinical experience with minoxidil indicate that

twice daily application for 4 or more months may be required befor evidence of hair

growth. Tugain should be used for not less than 45 days to arrest hair fall.

tugain 2% and Tugain 5% are available in squeeze pack bottles of 60ml.

2) Antiflu

The recent transmission of the highly pathogenic H5N1 avian influenza virus strain to

humans has highlighted the threat of pandemic influenza virus strain to humans has

highlighted the threat of pandemic influenza.

Oseltamivir (Antiflu) has proven to be safe and effective for the prevention of

treatment of all known influenza subtypes, reducing the severity and duration of

symptoms the complications arising from influenza infection (pneumonia,

hospitalization, antibiotic use) and mortality. Oseltamivir (Antiflu) in vitro studies has

been shown to be effective against pandemic strains of influenza, including the

currently circulating strain (H5N1).


INTEGRAL UNIVERSITY The recommended dose of Antiflu for the treatment of influenza, in adults

andadolescents 13years of age and older, is 150 mg per day, given as 75 mg twice a

day for five days. The recommended oral dose of Antiflu for prophylaxis of influenza

in adults and adolescents 13 years and older following cose contact with an infected

individual is 75 mg once daily for at least 10 days. Safety and efficacy have been

demonstrated for up to 6 weeks.

In patients with H5N1 infection (avian influenza), WHO recommends higher doses

than standard of Oseltamivir (keeping in mind that 300 mg/day is associated with

higher side effects) for a longer duration (7-10 days).


INTEGRAL UNIVERSITY

Primaglo- Keeps Her Going, Her KeepsGlowing

Premenstrual syndrome is a common cyclic disorder of young and middle aged

woman, characterized by emotional and physical symptoms that consistently occur

during the luteal phase of the menstrual cycle. Symptoms typically begin between the

ages of 25 and 35 years. More than200 symptoms have been associated with PMS

like

Behavioral symptoms: fatigue,insomnia, food cravings

Psychological symptoms: irritability, anger, depressed mood, crying,

Physical symptoms: headaches, breast tenderness and swelling.

Mastalgia means a generalized breast pain or tenderness perceived in 1 or both breast

It can be classified into 3 groups- Cyclical, Non Cyclical and Chest wall pain.

Cyclical mastalgia is common in 3 rd or 4 th decade of life and in 44% persists till

menopause. There is a relatioship between cyclical mastalgia and menstrual cycle,

which is mostly seen in luteal phase of the cycle. It is mostly bilateral, most severe in

upper & outer quadrants with associated diffuse benign nodularity. Patient complains

of heaviness/ tenderness of the breast. Primaglo is a natural vegetable oil processed

from the seeds of the evening primrose plant (Oenothera biennis). The oil provides a

valuable combination of the essential fatty acids (EFAs) linoleic acid and gamma

linolenic acid.


INTEGRAL UNIVERSITY The oil is an exceptionally rich and convenient source of essential fatty acids

Linoleric acid (LA) and Gamma linolenic acid (GLA)- which when converted to

prostaglandins E 1 (PGE1), aid essential bodily functions.

Primaglo is indicated for relieving symptoms of premenstrual syndrome such as

bloating breast tenderness, depression, irritability, headache; m astalgia and

menopausal symptoms e.g. especially night time hot flashes.

It is also used for psoriasis acne rheumatoid arthritis multiple sclerosis

hypercholesterolaemia heart disease alcoholism and diabetic neuropathy. Additionally

evening primrose oil has been shown to provide symptomatic relief in different forms

of eczema.

Usually, the treatment is started with 500 mg with each meal and then depending on

severity of the symptoms and the type of problem the dose can be increased upto two

capsules of Primaglo with each meal or as required. Primaglo is contraindicated in

patients of epilepsy.


INTEGRAL UNIVERSITY

Friday, March 30, 2007Cipla receives International Trade Awards 2006 for

outstanding exporter of the year (Pharmaceuticals, Healthcare and Life Sciences category)

Mr. Amar Lulla receiving the award at the International Trade Awards 2006

DHL and CNBC –TV18 announced the first ever International Trade Awards 2006. The

awards aim at recognizing corporates with the most outstanding and consistent business

and financial performance in its international trade category. The awards are targeted at

exporters-manufacturers, service providers, international trade houses as well as

importers who create value and export content.


INTEGRAL UNIVERSITY

November 15, 2006Cipla receives Scrip Award for Best Company

in an Emerging Market

Mr. Amar Lulla with Gyles Brandreth at the 2006 Scrip Awards "We are delighted and

honoured on being bestowed the Scrip Best Company in an emerging Market Award. the

award pays testament to the tremendous team effort of all Ciplaites who share their joy

on receiving this honour" commented Mr. Amar Lukka CEO of Cipla.

Scrip's Best Company in an Emerging Market Award honours achievement by a

pharmaceutical company in emerging markets of Asia, Central and Eastern, Central and

south America, the Middle East and Africa based on excellent performance across the

business, from growing sales and profits to new product launches.


INTEGRAL UNIVERSITY

Express Pharma/16-30June, 2006Cipla receives Pharma Excellence Award for 'Sustained

Growth"

Cipla walked away with the award for "Sustained Growth'. S. Radhakrishanan, CFO and

Sanjeev Gupta, Export Manager of Cipla received the award from A. K. Jha, Secretary-

Industries and Tourism, government of Goa and A. V. Palekar, MD Goa Industrial

Development Corporation.

The year 2004-05 saw a fall in the price of generics, primarily in the US market. Also, the

Indian markets were not that lucrative. This coupled with the post-WTO restriction and

focus on R&D had a serious impact on the revenue expectations of many Indian pharma

and biotech companies. In such a scenario, any company that manages to record an

impressive y-o-y growth, or even manages to maintain its performance levels, deserves

due recognition. The award for sustained growth tried to analyse the company

fundamentals over a period of three years to get an understanding of the company and the

direction in which it is heading. The award looked at growth through quantifiable

parameters like, sales, exports, market share, EBITDA and market capitalisation.


INTEGRAL UNIVERSITY

Gulfnews.com/November 27,2006(UAE)RAK honours Indian chief financial officers

by Nasouh Nazzal, Staff Reporter

Ras Al Khaimah: Akhil Gupta, Chief Financial Officer of leading Indian telecom services

provider Bharti Airtel, celebrated a triple success at the first CFO Awards for India

hosted by the Ras Al Khaimah Free Trade Zone and broadcast by CNBC-TV18.

The awards panel voted Gupta the Best CFO of the Year and Best Performing CFO in the

telecommunication sector, and to crown the evening he was also named the people's

choice as the Best CFO of the Year. Gupta received his awards at a glittering ceremony

in Ras Al Khaimah on Saturday night which was attended by Shaikh Saud bin Saqr Al

Qasimi, Crown Prince and Deputy Ruler of Ras Al Khaimah, Shaikha Lubna Al Qasimi,

UAE Minister of Economy, Shaikh Faisal Bin Saqr Al Qasimi, Chairman of the Ras Al

Khaimah Free Trade Zone, and Shaikh Salem bin Sultan Al Qasimi, Chairman of the

RAK Department of Civil Aviation.


INTEGRAL UNIVERSITY

October 01, 2006Helpage India felicaitates Cipla with Silver

Plate Award

Helpage India has felicitated Cipla Ltd., with SIL VER PLATE AWARD 2005-2006.

The award was received by Mr. Davinder Singh - Technical Director, Cipla from Mr.

Somnath Chatterjee, Honourable speaker, Lok Sabha at function organized by Helpage

India to celebrate International Day of Older Persons on 1st October 2006.

The award is given for Cipla's valuable contribution to society and Philanthropic support.

Cipla is known for its benevolence and has been instrumental in the growth and effective

development of Helpage India Mobile Medicare Units programme to a large extent.

Medicines thereby donated by Cipla have enabled the Mobile Medicare Units to expand

its network and quality of the treatment to the underprivileged elderly.


INTEGRAL UNIVERSITY

Cipla receives Dun & Bradstreet- American ExpressCorporate Awards 2006

Dun & Bradstreet-American Express Corporate Awards 2006" announced D&B

felicitates 20 of India's biggest corporate names and highest performers from 58 sectors

HIGHLIGHTS Due & Bradstreet (D & B), the world's leading provider of business

information, and American Express, Present the Dun & Bradstreet –American Express

Corporate Awards 2006 in association with Singapore Tourism Board, Lenovo and

Kingfisher Airlines Mr. M. Damodaran, Chairman of SEBI launches the 2006 edition of

the premier Dun & Bradstreet publication "India's Top 500 companies" The Awards

ceremony attended by over 300 chiefs of India's most Prestigious companies.

Mumbai, 17th August 2006: Dun & Bradstreet (D&B) the world's leading provider of

global business information, knowledge and insight, today announced and presented the

'Dun & Bradstreet- American Express Corporate Awards 2006' in Mumbai. The occasion

market the launch of the premier Dun & Bradstreet India(D&B India's Top 500

Companies 2006 by Mr. M. Damodaran, Chairman, Secrities and Exchange Board of

India (SEBI).


INTEGRAL UNIVERSITY

DNA, Mumbai Thursday, Novermber 10,2005)Cipla to keep ready 2 lakh doses of bird flu drug

Rabin Ghosh

MUMBAI: For some time now, Uusuf Hamied, chairman and managing director of

generic drug maker Cipla has been talking about making a drug to combat the dreaded

bird flu. He said that the would manufacture 100,000-200,000 dosages of the bird flu

drug Tamiflu for emergencies.

However, as per international patent laws, the company would not be allowed to sell the

product in the signatory countries.

This means that Cipla would not be able to market the drug in the lucrative US and

European markets.

"We are planning to manufacture that bulk drug and store it and hope that we never have

to use it," he said. Hamied denied that Cipla had already spoken to Roche about a

possible contract manufacturing deal, but would approach the Swiss pharmaceutical

major shortly. Roche currently holds the worldwide patent for Tamiflu. "We would like

Roche to give us the licence for the countries where the drug is patent protected, "Hamied


INTEGRAL UNIVERSITY said. Cipla doesn't require Roche's approval for selling the drug in markets not covered

by the patent protection laws.

Cipla's entry in the Tamiflu segment is expected to drive down the price, similar to what

had happened in the HIV medicine market. Currently Riche retails Tamiflu at $60 for a

strip of 10 tablets.

The generic bulk drug used to manufacture Tamiflu is Oseltamavir, which Cipla plans to

manufacture. Another drug used to treat flu is Relenza, manufacture by Glaxo Smith

Kline. Cipla is also toying with the idea of manufacturing Relenza's bulk drug

Zanamavir.

However, sourcing the raw material for the drugs-is chemic acid for Oseltamavir, and

macetyl neuraminic acid – is posing to be a challenge, since limited number of players

manufacture them.


INTEGRAL UNIVERSITY

(The Hindu, Hyderabad, Sunday, Sep 04, 2005)Cipla chairman wants relook at patents bill

V. Krishnamurthy award for 2005 for excellence presented

AN HONOUR : The Director, Tata Sons LTd, J.J. Irani, presenting the V. Krishnamurthy

award for excellence to the Chairman of the Cipla, Yousuf K. Hamied (second left), in

Hyderabad on Saturday. The former CND of the Madura Coats, M.B.S. Henry, and the

Chairman, ONGC, Subir Raha (extreme right), look on. Photo: Mohd. Yousuf.

HYAERABAD: The chairman and managing director Cipla Limited Yusuf K. Hamied

on Satureday urged the Government to reexamine the recently passed Patents Bill saying

it would eventually be harmful to the majority of people. Accepting the V.

Krishnamurthy award for 2005 for excellence from J.J. Irani Director of Tata Sons here

on Satureday he said that India must decide its own destiny.

Disease profile

"We cannot blindly follow directives emanating from the corridors of power be it in

London or Washington".

Giving an account of the disease profile in the country-80 million cardiac parents 60

million diabetics 110 million patients with mental illness, 50 million asthmatics and an

equal number of Hepatitis B cases, he said the Worlds Bank had estimated that India will


INTEGRAL UNIVERSITY have 35 million HIV positive cases by 2015, about 50 per cent og the world's total at that

time.

The ONGC chairman, Subir, read out the citation of the award, instituted by the city-

based Center for Organisation Development (COD). Mr. Irani, lauding the leadership

qualities of Mr. Krishnamurthy, said that a successful leader should have vision,

perseverance, clarity and credibility.


INTEGRAL UNIVERSITY

Express Pharma Pulse, Mumbai, Thursday, July 21, 20055th Express Pharma Pluse Awards

Group a Winner: Cipla

This is our 70th year, and the awards are a good landmark to remember it by with a

growth rate of 6.6 percent, Cipla has outpaced the industry-average growth rate of 6.4

percent. In the domestic market, Cipla has over 1000 products of which 55 were launched

last year. The company has introduced several new products and line extensions

including Duova Rotacas and inhalers for COPD, Duovir E Kit for HIV management and

a range of asthma products with a unique in-house multihaler device for delivery of the

active ingredient.

"Out ranking in the domestic market can primarily be attributed to the fact that we have

one of the largest product portfolios in the industry", says Cipla's Joint MD, Amar Lulla,

"The WHO rejection of our anti-retroviral did affect business, but later it was found that

the bio-study lab analyzing the product was at fault. The name of our product was cleared

and the sales recovered", reveals Davinder Singh, Techncial Director, Cipla. Apart from

the new produced launched, Cipla has taken many new initiatives in the past year in the

areas of manufacturing, research & development and marketing. The company came up

with new manufacturing facilities in Goa and Baddi. It also entered into a research

alliance with a Banglore-based biotech company to develop biopharmaceutical products.


INTEGRAL UNIVERSITY A number of patents, local as well as international, were also filed during the year. "We

conducted a number of activities to celebrate our 70 years in the industry, among which

was our initiative to conduct AIDS awareness drives in schools and other forums",

discoloses Singh. Cipla's initiatives in the coming year include expanding into new

markets and new products. "Predominantly, we intend to come out with a suit of hormone

products, anti-cancer drugs and a new range of lyophilisers", declares Singh.


INTEGRAL UNIVERSITY

Japan Chemical Weekly / Monday, April 16, 2007India's Cipla in talks to Ally with Generic Companies in JAPAN

Scrip – World Pharmaceutical News/ Thursday, April 05, 2007

Chipla launches cut-prize zanamivir in India

Chipla has launched Virenza inhalation capsules (Zanamivir), a generic version of

GlaxoSmithKline's Relenza, in India for the treatment of influenza and avian flu caused

by the H5N1 virus.

Cipla says it is the first company to launch a generic version of the product. It will be

available for inhalation using a novel, dry-powder inhaler, the Revolizer, the company

added.

Cipla's CEO, Amar Lulla, told Scrip that the product will be available at discount of

about 40% to Relenza's US price. The company will also export the product to markets

that are not patent-protected, he added.

Last year GlaxoSmithKline entered into an agreement with the US government to provide

states with Relenza as they prepare for a potential influenza pandemic. The Department


INTEGRAL UNIVERSITY of Health and Human Services had, at the time, guaranteed the initial purchase of $16.8

million worth of Relenza (Scrip No 3178, p19).

Cipla has been at the forefront of launching cut-price generic products across therapeutic

segments. Last year, it launched oseltamivir (market as Antiflu), a generic verson of

Gilead Sciences/Roche's Tamiflu.

The domestic launch of generic zanamivir is expected to be less controversial as Relenza

does not quality for patent protection in India, since it was patented prior to 1995 – the

cut off date to quality for patent protection in India.


INTEGRAL UNIVERSITY

DNA, Mumbai, Saturday, Novermber 19, 2005)Cipla strikes deal with US company for anti-infective

Mithun Roy

MUMBAI: Leading pharmaceutical company Cipla Ltd has entered into a deal with US-

based Akorn Inc to develop and supply a generic oral anti-infective drug. Under the deal,

Cipla will develop and make the drug, while Akorn will make the regulatory submissions

and do the clinical development. Akorn will pay Cipla development fees as and when

milestones are reached. Akorn will have exclusive marketing rights for the drug in the

United States. Sources said Akorn Inc has already signed a letter of intent with Cipla to

develop and supply an oral anti-infective abbreviated new drug application drug product.

The letter of intent anticipates executing a definitive agreement within 90 days upon

terms and conditions agreeable to both Akorn and Cipla. Amar Lulla, joint managing

director, Cipla said, "The drug will hit the US market in the next 18 months." He refused

to divulge the size of the deal and name of the drug. Akorn has manufacturing facilities

located in Decatur, Illinois and Somerset, New Jersey and markets and distributes an

extensive line of hospital and ophthalmic pharmaceuticals. The drug is distributed and

used mainly is US hospitals and has a current market size of $100 million. This could be

a windfall for Cipla. Its exports have jumped 32.63% year-on-year to Rs. 320.5 Crore in

the September quarter. This was driven largely on a surge in its formulations business.


INTEGRAL UNIVERSITY

The Times of India, Mumbai, Thursday, November 10, 2005)Akorn, Cipla pact for anti-infective

Mumbai: US based Akorn Inc has signed a letter of intent with Mumbai-based

domestic pharma major Cipla, to develop and supply an oral anti-infective abbreviated

new drug development application (ANDA) drug product. Akorn will pay, Cipla product

development milestone fees of an undeclared amount. The US firm has agreed to

purchase the product from Cipla and will own the ANDA with exclusive marketing rights

in the US. The oral ANDA anti-infective drug product is distributed and used primarily in

US hospitals and has a current market size of approximately $100 million. While Cipla

will be responsible for the development and manufacturing of the drug, Akorn will be

responsible for the ANDA regulatory submission and clinical development. The letter of

intent anticipates executing a definitive agreement within ninety days upon terms and

conditions agreeable to both Akorn and Cipla. Speaking about the tie-up, Arthur Przybyl,

Akorn's chief executive officer said: "Over the years, Cipla has demonstrated its ability to

successfully develop and manufacture drug products for the US marketplace. This

product is an excellent fit for Akorn's distribution channel strategy because the product

sales are primarily driven by hospitals."


INTEGRAL UNIVERSITY

The Economic Times/ Mumbai 29,2006Cipla gets US approval for AIDS generic

MUMBAI: The US Food and Drug Administration has tentatively approved Indian drug

maker Cipla Ltd's oral form of anti-AIDS generic efavirenz, the Us regulator said on its

web site.

Efavirenz is an anti-viral that is used with other AIDS combinations to help block the

spread of HIV, the virus that causes AIDS.

(The Economic Times/ Mumbai May 23,2006)Cipla gets tentative FDA approval for AIDS drug

REUTERS

Drug maker Cipla Ltd has received tentative approval from the US Food and Drug

Administration for generic AIDS drug nevirapine in the tablet form, according to an FDA

statement. Also, Sun Pharma Ltd has received tentative approval for ondansetron in the

injection form.

Ondansetron, used for prevention of nausea and vomiting caused by chemotherapy or

radiation therapy, is the generic equivalent of Glaxo Smith Kline's Zofran injection.


INTEGRAL UNIVERSITY

(The Hindu Business Line / Mumbai May 02,2006)Cipla opposes patent application on bird-flu drug

P.T. Jyothi Datta

Cipla has opposed the patent application on Oseltamivir, a drug that become popular at

the peak of bird-flu epidemic. The pre-grant opposition was filed at the Patent Office in

New Delhi earlier this month.

Oseltamivir was developed by Gilead Sciences and is sold globally by Roche under the

Tami flu brand name. It is much sought after by Governments across the world as they

stockpile the drug in the event of bird-flu jumping species from birds to human.

Cipla's Joint Managing Director, Mr. Amar Lulla, told Business Line that the pre-grant

application had been "filed on the grounds of known prior-art, invalid claim, lack of

novelty and inventive step".

Times of India / New Delhi July 13,2006)Firms ready with cheaper AIDS drugs

Rupali Mukherjee

There is good news for HIV patients. The first three-in-one combination single pill to

treat AIDS will soon be launched by Indian drug companies at around Rs 1 lakh (per

annum, per patient) --- or around Rs 274 per day---- which will be 80-85% cheaper than

the global price of nearly Rs 7 lakh per patient per year ($ 15,000).


INTEGRAL UNIVERSITY The single once-a-day pill will make the treatment cheaper and easier as against

struggling with dozens of pills in a day.

The single pill, which is a combination of three drugs, also got US FDA nod on

Wednesday. The pill, Atripla, which contains Bristol-Myers Squibb Co's drug Sestina

and Gilead Inca's medicines Viread and Emtriva, is the latest step in making it easier for

AIDS patients to keep HIV in check.

Sources said that major Indian companies including Cipla and Hetero Drugs are already

working on it, and may launch it close to the worldwide launch by foreign companies.

Cipla joint Md Amar Lula said, " We are ready with the formulation for the three-in-one

single pill, and are applying to the Drug Controller of India for approval". The company's

single once-a-day pill will be branded as Viraday. He added that foreign companies have

started following the example set by Cipla in launching fixed dose combinations to treat

HIV.

IN 2001, Cipla launched the first fixed-dose combination, Triomune that combined thee

antiretroviral drugs in one pill (twice a day), and offered it at $350 (Rs 15,000) per

patient, per year as against global price of $10,439 (Rs5 lakh).

This also became one of the frequently prescribed treatments in developing countries,

making the treatment simpler and cheaper.

Hyderabad-based Hetero Drugs is also working on the fixed dose single pill and will

launch it in a few months. The company's director marketing, M Srinivas Reddy said:

"We are waiting for the license to initiate studies on the drug, and will launch it

substantially cheaper than the global price".


INTEGRAL UNIVERSITY Experts say that with more competition coming in, prices of these drugs would go down.

Recently, Aurobindo Pharma got FDA approval to produce a generic version of a three-

combination drug.


INTEGRAL UNIVERSITY

The Financial Express / Monday, December 12, 2006LTT Bio-Pharma ties with Cipla

REUTERS

Tokyo, December 11: Japan Bio-venture firm LTT Bio- Pharma Co.Ltd. said on Monday

it had tapped Indian drug maker Cipla Ltd to help it develop Nan steroids, which have the

potential to be more effective and produce fewer side effects than conventional steroid

treatments.

LTT Bio-Pharma, whose stock shot up nearly 4 percent on the news, said that as part of

the deal, it would outsource the production of Nan steroids to Cipla.

The company has good results in animals with Nan steroids and says it hopes to begin

clinical trials within two years.

Nan steroids are a drug delivery system in which steroids are inserted into a polylactic

acid particle with a width of only 150 nanometers.

The use of the particle, which is delivered by intravenous injection, allows for a slow

release time so that the drug can be effective for up to a week, the company said.


INTEGRAL UNIVERSITY Nan steroids also allow a targeted delivery that should help reduce side effects, which can

be severe in conventional steroid treatment. Steroids are used to treat a variety of diseases

including arthritis and allergy-related diseases.

LTT Bio-Pharma said there were many bio-venture firms around the world working in

nanomedicine but it believed it was the only one working on nanosteroids, which are

much difficult to make than other medicines.

LTT Bio-Pharma shares, listed on the Mothers start-up section of the Tokyo Stock

Exchange, were up 1.9 percent at 108,000 yen in afternoon trade.


INTEGRAL UNIVERSITY

Lopimune Tablets-No More Restrictions

Recently Cipla has made available a new heat stable tablet formulation of the HIV

protease inhibitor Lopimune (lopinavir /ritonavir). This will adult patients to take fewer

pills with or without food as part of their treatment regimen. Additionally, there will be

no refrigeration requirements for the tablets. All theses benefits were not available with

the old Lopimune soft gelatin capsules. As per the Indian API guidelines, Lopimune is a

recommended second line option for treatment after patients have used a first line

regimen containing efavirenz or nevirapine. Western guidelines recommend that

lopinavir/ ritonavir can be used as a first line option for initiating therapy.

The benefits of Lopimune tablets include:

Fewer tablets per dose as part of a treatment regimen in adults. While the total

daily dose of Lopimune (lopinavir/ritonavir) is unchanged, the number of

Lopimune pills that adult patients need to take is reduced from 6 capsules to

four tablets per day.

The tablet formulation of Lopimune can be taken with or without food,

whereas the capsules needed to be taken with food. This would greatly

enhance patient adherence.

Lopimune tablets do not need to be refrigerated, unlike the older capsule

formulation, which makes it convenient for the patient, especially in resource-


INTEGRAL UNIVERSITY limited settings, where access to refrigeration and continuous supply of

electricity may not always be possible.

Thus, the introduction of Lopimune tablets represents a significant patient-friendly

advance in HIV therapy.

Tuela – Stops Pain Active Again

Each tablet of Tuela contains Drotaverine Hydrochloride (80mg) and Mefenamic acid

(250mg.) Drotaverine is an antispasmodic agent with smooth muscle relaxant properties.

It is a phosphodiesterase enzyme IV inhibitor, a non-anticholinergic antispasmodic.

Mefenamic acid is a nonsteroidal anti-inflammatory drug (NSAID) with demonstrated

anti-inflammatory, analgesic and antipyretic activity. The drug inhibits prostaglandin

synthesis and competes for binding at the prostaglandin receptor site. Tuela is a non-

hormonal, safe and effective treatment for primary and secondary dysmenorrhoea.

Dysmenorrhoea affects up to 50% of menstruating women, and 10% are incapacitated for

up to 3 days, making normal everyday activities very difficult.

Tuela reduces menstrual blood loss significantly and also alleviates pain due to various

conditions. Unlike dicyclomine, Tuela does not lead to dryness of mouth, tachycardia,

drowsiness or constipation. It has better patient compliance and excellent tolerability

profile.

Tuela is indicated in the management of following conditions:


INTEGRAL UNIVERSITY Primary and secondary dysmenorrhoea

Post surgical uterine spasm

Gastro-intestinal colic, renal colic, biliary colic

Uterine irritability and pain associated with IUCD insertion, dilatation and

curettage, pelvic inflammatory disease or HSG.

The recommended dosage regimen for Tuela is one tablet three times a day or SOS.


INTEGRAL UNIVERSITY

Global Presence

Exports for the financial year ended March 31, 2006 amounted to more than Rs. 15,000

million. Cipla exports raw materials, intermediates, prescription drugs, OTC products and

veterinary products. Cipla also offers technology for products and processes. Technical

know-how/fees received during the year 2005-06 amounted to Rs. 4156 million. Cipla's

manufacturing facilities have been approved by the following regulatory authorities:

Food and Drug Administration (FDA), USA Medicines and Healthcare Products

Regulatory Agency (MDRA), UK Therapeutic Goods Administration (TGA), Australia

Medicines Control Council (MCC), South Africa National Institute of Pharmacy (NIP),

Hungary Pharamaceutical Inspection Convention (PIC), Germany World Health

Organisation (WHO) Department of Health, Canada State Institute for the Control of

Drugs, Slovak Republic ANVISA, Brazil

Cipla products are bought by over 160 countries located in the following regions:


INTEGRAL UNIVERSITY

Financial Profile

UNAUDITED FINANCIAL RESUFLTSFOR THE QUARTER ENDED 31st MARCH, 2007

(Rupees in crores)

31-03-07 31-03-06 31-03-07 31-03-06(Audited)

1 Gross Sales & Income from Operations

960.38 905.70 3667.05 3114.20

Less: Excise Duty 21.91 23.14 94.91 128.32Net Sales &Y Income from Operations

938.47 882.56 3572.14 2985.88

2 Other Income 22.06 36.69 89.13 121.633 Total Expenditure

a) (Increase)/ decrease in Stock-in-trade

28.46 (14.16) 33.82 (94.35)

b) Consumption of Materials

469.01 445.41 1694.17 1505.92

c) Staff Cost 43.34 42.57 184.29 150.76d) Other Expenditure 250.67 218.37 837.13 743.74

4 Interest 1.29 3.29 6.96 11.425 Depreciation 26.08 25.00 104.08 80.186 Profit(+)/Loss(-) be fore

Tax(1+2-3-4-5)141.68 198.77 800.82 709.84

7 Provision for Taxation—Current Tax 12.50 7.00 124.00 89.00—Deferred Tax 2.50 12.50 9.00—Fringe Benefit Tax 0.95 1.00 3.50 4.20

8 Net Profit(+)/Loss(-) after Tax (6-7)

125.73 190.77 660.82 607.64

9 Paid-up Equity Share Capital

*155.46 59.97 *155.46 59.97

10 Reserves excluding Revaluation Reserves

1913.97

11 **Earning per Share (Rs.)

1.62 2.54 8.52 8.11


INTEGRAL UNIVERSITY 12 Aggregate of Public

Shareholding—Number of Shares —Percentage of Share-holding

162223309

59.47

77494293

59.19

162223309

59.47

77494293

59.19

Notes:

The Company is exclusively in the pharmaceutical business segment.

The paid-up equity share capital stands increased to Rs. 155.46 crores

(77,72,91,357 equity shares of Rs.2 each) upon allotment of 1,10,46,310

shares underlying Global Depository Receipts (GDRs) and 46,63,74,814

bonus shares during the quarter ended June 2006.

** The quarterly Earnings Per Share (EPS) figures are not annualized and previous

years' EPS figures are adjusted for the bonus issued.

No investor grievances were pending at the beginning of the quarter. During the quarter

ended 31st March, 2007, fourteen investor grievances were received. As of 31st March,

2007 all grievances have been suitably replied to.

During the period under review the Company's subsidiary set up at Jebel Ali, Dubai did

not undertake any purchase or sale transactions. Consequently, the effect of consolidation

in the Company's books is not significant and therefore consolidated figures have not

been given separately.


INTEGRAL UNIVERSITY

The figures of the previous year have been regrouped/recast to render them comparable

with the figures of the current year.

The above results after being reviewed by the Audit Committee were approved and taken

on record at the meeting of the Board of Directors held on 26the April 2007.

By order of the BoardFor CIPLA LIMITED

Mumbai26th April, 2006

M. K. Hamied Joint Managing Director


INTEGRAL UNIVERSITY

Financial Review – Period ended March 2007

Financial performance:

(Rupees in crores)

Quarter Ended Year Ended

31-3-07 31-3-06 %change 31-3-07 31-03-06 %change

Domestic 399.72 349.52 14.4% 1752.28 1506.04 16.4%Exports

Formulations 387.87 332.04 16.8% 1297.82 1029.81 26.0%APIs 141.46 194.59 27.3% 482.92 483.83 0.2%

Total Exports 529.33 526.63 0.5% 1780.74 1513.64 17.6%% of exports to total

Sales57.0% 60.1% 50.4% 50.1%

Total Sales 929.05 876.15 6.0% 3533.02 3019.68 17.0%

Other operating incomeTechnology

Knowhow/fees24.20 6.18 76.44 41.56

Others 7.13 23.37 57.59 52.96

Total 31.33 29.55 6.0% 134.03 94.52 41.8%Income from Operations 960.38 905.70 6.0% 3667.05 3114.20 17.8%

Operating margin 146.99 190.37 22.8% 822.73 679.81 21.0%% to income from

operations15.3 21.0 22.4 21.8

Profit before tax 141.68 198.77 28.7% 800.82 709.84 12.8%% to income from

operations14.8% 21.9% 21.8% 22.8%


INTEGRAL UNIVERSITY

Profit after tax 125.73 190.77 34.1% 660.82 607.64 8.8%% to income from

operations13.1% 21.1% 18.0% 19.5%

The overall performance for the year 2006-07 in terms of income from operations and

profit after tax with a growth of about 18% and 9% respectively has been in line with the

estimates of the company.

During the last quarter 2006-07, domestic sales and formulation exports grew by about

14% & 17% respectively, while APLs exports were down by about 27% mainly on

account of higher sales to regulated markets in the corresponding quarter of the previous

year. Income from operations has increased by 6% for the last quarter.

During the quarter, material cost (as a percent to income from operations) has increased

from about 48% to 52% due to change in product mix, in particular higher volume of

anti- retrovirals and lower API sales to regulated markets.

Other expenditure for the quarter has increased by about 15% mainly on account of

increase in factory overheads such as power & fuel, repairs and stores & spares as well as

other expenditure such as selling expenses, professional fees, etc.


INTEGRAL UNIVERSITY Tax for the quarter is in line with the 9 months period ended December 2006. Other f

income has reduced in the current quarter mainly on accounts of insurance claims (about

Rs. 20 crores) received during the previous year.

The increase in material cost and overheads has resulted in a decline in operating margins

from about 21% to 15% during the last quarter 2006-07.


INTEGRAL UNIVERSITY

LIST OF PRIVATE PEDIATRICS

1. Dr. K.N. Khanna ADDRESS: Goal Darwaja, Chowk Chauraha TIMING: 11:00 to

2:00(mor)& 8:00 to 10:00 (Eve)

2. Dr.M.v.Hasan (M.B.B.S.,M.D.) ADDRESS: Near Medical College Chowk

TIMING: 10:00 to 1:00 (mor) & 6:00 To 9:00 (Eve) Contact:

9415091406,9336141042

3. Dr.V.B.Panday ADDRESS: Tulsidhar Marg Modi Chowk TIMING : 11:00 to

12:00 (mor) & 3:00 to 4:00 (Eve)

4. Dr.V.B.Panday(M.B.B.S.,N.D.N.,Dip.) ADDRESS: Amirudaula Park Near

Gulmarg Hotal TIMING: 12;00 to 3:00(mor) & 7:00 to 9:00 (Eve) Contact:

9415105595,9415111106,2230919 M.R. Time:1:00 to 2:30 (Noon)

5. Dr.Ajay Kumar ADDRESS(Home) Mother Child Care Center Apisane Road,

Charbag CLINIC: Puran Nagar, Alambag Kanpur Road TIMING: 8:00 to 9:00

(Eve) & 1:00to2:00(Sun) Saturday closed Contact:2635629

6. Dr.Rajeev Singh ADDRESS:( Clinic) Opposite to Aryan Restaurent, Sahu

Plaza ,Alambag Contact: 3465640Timing 11:00to 4:00 M.R. Time-1:00To 2:30

Address Home-Biraj Maternity & Child Care Parag Chauraha Time:9:00 to

10(mor)&6:00to9:00(Eve) M.R.Time:12:00to1:00


INTEGRAL UNIVERSITY 7. Dr.Rajkumar Thakur Address-Sujanpura, Alambagh TIME: 10:00to2:00 (Mor) &

6:00 to 9:00(Eve) M.R. Time: 12:00to 1:00

8. Dr.O.P.Tondon Address-Pandariba,L.K.O Time 9:30 to 2:30 (mor) & 6:00 to

10:00 (Eve) M.R. Time-12:00 to 1:00 Contact-250156 (Saturday & Sunday

Evening closed)

9. Dr. Satish Chandra Address- 4, DAV College Compound Aishbagh Road

Timing : 8:00 to 9:30 (mor) & 5:30 to 8 (Eve) SUNDAY – 9:00 TO 1:00 (MOR)

Contact-2692952

10. Dr. P.S Saluja (M.B.B.S.,D.C.H) Address-Naka Hindola, Aishbagh Road Timing:

10:00 to 1:00 (Mor),6:30 to 9:00 (Eve) Contact- 9935175098, 9335232220

11. Dr. Surendra Rastogi Address- Subhash Marg, Dugawa Timing:- 10:00 to 1:00

pm, 6:00 to 9:00 pm

12. Dr. Mukesh Kesarwani Address- Deep HOTEL, Hussaingunj Timing- 9:30 to

12:30 pm, 7:00 to 9:30 pm Sunday – 10:00 to 1:00 pm

13. Dr.Shalini Bhasin Address- Ram Kishan Marg backside of CENTRAL BANK

Timing- 9:00 to 12:30 pm 5:00 to 8:00 pm Contact- 2327820,232227914

14. Dr. P.K Agarwal Address-Puran Nagar, Kanpur Road Alambag Timing- 11:00 to

1:00 pm, 7:00 to 9:00 pm Sunday – 11:30 to 1:00 pm Contact- 9335231987

15. Dr. Atul Rastogi Address- Shringar Nagar , Alambagh Timing- 10:00 to 1:00 pm

6:00 to 9:00 pm Contact- 2454029 (clinic), 2471638(resi)

16. Dr. Jaspal Singh Address- Naka Hindola Road, Aishbagh Timing- 1:30 to 2:00

pm, 7:00 to 10:00 pm Sunday- 10:30 to 1:30 pm Contact- 9451251400, 2681824


INTEGRAL UNIVERSITY 17. Dr. Ashish Mathur Address- Care Energy, Dawakhana, Sadar Bazar Chouk

Timing- 6 to 9 pm Contact – 2480809, 2621684

18. Dr.Manju Agarwal Address- Maulana Cantt Guru Chand Road Sadar Bazaar

Timing – 8 to 1 pm, 6 to 9 pm Contact- 391723

19. Dr.Anand Vardhan Singhania Address- Arudthaya 278 Vanay Khand Ist Gomti

Nagar Timing – 8 to 10 am, 6 to 9 pm Contact- 391723

20. Dr. K.S. Monga Address- Sringar Nagar Alambagh , Kanpur Road Timing – 10 to

1 pm, 6 to 9

21. Dr. M. Mohan Kumar (M.B.B.S,D.C.H) Address- gupta Ji Ka Dawakhana, in

front of Krishna Nagar Kotwali Timing – 10:30 to 1 pm, 7 to 9 pm

22. Dr. Rama Bhatnagar Address- Haldi Khera, Kanpur Road Timing- 9 to 8 pm M.r

Time- Tue-12 to 2 pm Thu-12 to 2 pm Sat-12 to 2

23. Dr. Amit Kumar Verma Address- AMY Child Care Clinic Purani Chungi Hing

Nagar, Kanpur Road Timing- 9 to 11:30 am, 7 to 9 pm

24. Dr. V.B. Singh Address- Arudthaya 278 Vinay Khand Ist Gomti Nagar Timing –

8 to 10 am, 6 to 9 pm Contact- 391723

25. Dr. R.K Verma (M.B.B.S, C.H) Address- LDA Corner Krishna Nagar Timing- 10

to 1 pm, 6 to 9

26. Dr. Sanjay Jaiswal Address- Model House Timing- 10 to 1 pm, 6 to 9 pm

27. Dr. K.K Tripathi Address- Near Odian Cinema Timing- 10:30 to 12:30 pm, 6:30

to 9:30 pm

28. Dr. Anand Kishore Address- Civil Hospital Timing- 10 to 1 pm


INTEGRAL UNIVERSITY 29. Dr. Abhishek Verma Address- Prashit, Child Clinic 1/100 A Viram Khand Gomti

Nagar Timing-5:30 to 9 pm

30. Dr. Ajay Krishna Address- C.V netralay, Viram Khand Gomti Nagar Timing – 9

to 11:30 am, 7 to 8 pm Sun-8:30 to 11:30 am

31. Dr. A.P Panday Address- 5/28 Viram Khand Gomti Nagar Timing- 10 to 12 am, 6

to 8:30 pm

32. Dr. Praddep Sharma Address- Bhoot Nath , Indira Nagar Timing- 10 to 12:00 pm

6 to 8:30 pm

33. Dr. D. K. Majumder Address- Babuchand Marg ,Aligang Timing – 10 to 1 pm, 6

to 9 pm

34. Dr. R.G Agarwal Address- Kapurthala Timing- 9:30 to 12:30 pm, 4:30 to 8:30 pm

35. Dr. Rita Bakshi Address- B-387 Indira Nagar Timing- 10 to 12 am, 6 to 8 pm

36. Dr. Rashmi Sharma Address- B-1308 Indira Nagar Timing – 10 to 12 am, 6 to 8

pm

37. Dr. Vijay Prakash Address- Lakh Raj Palace Bhoot Nath, Indira Nagar Timing-

8:30 to 10:30 am, 6:30 to 8:30 pm

38. Dr. Ramesh Modi Address-Bashudave Child Care, Agarwal Plaza, Church Road

Sarvodaya Nagar, Indira Nagar Timing- 8 to 9:30 am, 6 to 8:30 pm

39. Dr. A.K Verma (M.B.B.S, M.D) Address- Sant Joseph,Hospital, C- 2370, Indira

Nagar Timing- 7 to 8 am, 2 to 3 pm, 6 to 10 pm Contact- 9839089844

40. Dr. A.B Garg Address- 13/556, Indira Nagar timing- 11 to 1 pm, 5 to 7 pm


INTEGRAL UNIVERSITY 41. Dr. S.S Verma Address- Arushi Clinic, 10/8/2, Indira Nagar Timing- 8 to 11 am,

6 to 9 pm

42. Dr. Navneet Goyal (M.B.B.S,d.C.H) Address- Tulsi Plaza, opposite to Central

Academy Sec-12 Indira Nagar Timing- 9 to 12 am, 6to 9 pm

43. Dr. K.K Mishra Address- Victoria Street Timing-6 to 9 pm

44. Dr. Pankaj Bhamari Address- B Blick Indira Nagar Timing- 10 to 1 pm,6 to 9 pm

45. Dr. Abdul Haleem Address- Victoria Street Timing- 10 to 3 pm

46. Dr. Arvind Dubey Address- Era Hospital. Nakhas Timing- 10 to 12 am

47. Dr. A.K. Rastogy Address- Tulsidas Marge Near Yashodhara Girls College Tulia

Gangh timing- 9:00 to 12:00 am.

48. Dr. V.K.Kharay Address- Lalbagh Timing- 5:00 to 6:00 pm

49. Dr. A. C. Chawala Address- Basant Cinema Lalbagh Timing- 9:00 to 12:00 am,&

6:00 to 9:00 pm

50. Dr. Anjana Arora Address- 2/9 Viramkhand Gomtinagar Timing- 9:00 am, to

1:00 pm & 7:00 to 10:00pm

51. Dr. V.Singh Address- Vinay Khand, Gomtinagar Timing- 10:00 to 12:00 am.& 6

to 9:0 pm

52. Dr. Sleem Lawrence Address- Cent Josaf Hospital Gomtinagar Timing- 1:00 pm,

to 2:00 pm

53. Dr. Shalash Agrawal Address- Nova Hospital, Gomtinagar Timing- 9:00 to 12:00

am

54. Dr. Rita Bhagdi Address- B-Block Indira Nagar Timing- 9:00 to 1:00 pm


INTEGRAL UNIVERSITY 55. Dr. Shalini Tondon Address- Hyran Medical Store Maha Nagar Timing- 10:00 to

1:00 pm & 6:00 to 9:00 pm

56. Dr. Sanjay Niranjan Address- New Goal Market, Maha Nagar Timing- 10:00 to

1:00 pm & 6:00 to 9:00 pm

57. Dr. S.M. Ratogy Address- Rani Gang Timing- 10:00 to 1:00 pm & 6:00 to 9:00

pm

58. Dr. Shubhash Mishra (M.B.B.S) Address- Ganeshgang Timing- 10:0 to 1:00 pm

& 5 to 8:30 pm

59. Dr. V.P. Singh Address- Barabari Caserbagh Timing- 10:00 to 1:00 pm & 6 to

9:00 pm

60. Dr. Prasant Bhargave Address- Sai Child Care Clinic KDT Plaza Ram-Ram Bank

Chauraha Sec- Q Aligangh Timing- 10:00 to 1:00 pm & 6 to 9:00 pm

61. Dr. Ravi Arora (MBBS, DCH) Address-(Clinick) B/V-69 Sec-JK(Near

Vindhayachal- Mandir) Aligangh (Home) B 1/68 Sec- K Timing- 10:00 to 1:00

pm & 6 to 9:00 pm

62. Dr. Deepti Goal address- UGF-28 Arohi Complex Piranha Crossing – Aligangh

Timing- 9:00am to 12:00 am & 6:00 to 9:00 pm

63. Dr. Manoj Kumar Address- Sec-B Sitapur Road S.B.I. Nagar Aligunj Timing- 9

to1:30 pm, 5:30 to 8:30 pm

64. Dr. B.L Rastogy address- S.B.I Colony, Sec-B Aligunj Timing 8 to 1 pm, 4 to 8

pm

65. Dr. Ravi Laley Address- Vivekanand Timng- 10 to 12 am


INTEGRAL UNIVERSITY 66. Dr. Prashant Arora Address- Vardan Clinic, Viram Khand- A Timing- 10 to 1 pm,

6 to 9 pm

67. Dr. B.P Singh Address- Vinay Khand Gomti Nagar Timing- 10 to 1 pm, 6 to 9 pm

68. Dr. Shailesh Goal Address- Patrakar Puram Gomti Nagar Timing- 10 to 1 pm

Contact- 9415283684

69. Dr. Harsh Gupta Address- Shakupura Colony, Aligunj Timing- 9 to 2 pm

70. Dr Ashutosh Mishra Address- Ram Nagar Bank Chauraha Aligunj Timing- 10 to

12 am, 6 to 9 pm


INTEGRAL UNIVERSITY

TO STUDY THE MARKET SHARE OF ANTIBIOTIC

Name of medical store - Chandra medical store

Name of doctor - Dr.P.S.Saluja

Timing... 10 am to 1 pm& 6 to 9 pm.

Address - Nace hindola aishbag road

Q.1 which brand/company antibiotic they are using

(A) Cefriaxone plus tazobactum X-pzone250mg (1 unit per day=30&500mg one

week=4)

1. X-Pzone250mg (two unit per day=60&500mg two unit per week=8)

2. X-P250mg switch 1 unit/day=30,500mg 1 unit/week=4

3. X-P250mg praxol 2 unit/day=60,500mg 1 unit/week=4

(B) EMESET (CIPLA)-1 unit/day=30

1. Onedem-alken -2 unit/day=60

2. vomikiaind-Mankind -2 unit/day=60

3. Ondomac-Maclods - 1 Unit/day=30

4. Emigo-Zuentus -2 Units/day=60

(C) Biozova (pre&probiotic)-cipla-1unit per Day=30

Darolac-aristo -2unit/day=60

Eubioz-Lupin -3 unit per Day=90


INTEGRAL UNIVERSITY Bifilac-tabletindia -2 unit per Day=60

Flora-SB-Mankind -3 unit per Day=90

(D) Nitazd (Nitazoxauide) – Cipla- 2 unit per Day=60

Nizonid-Lufin -2 unit per =60

Zoxakind-mankind -1 unit per Day=30

Netacur- alembic -2 unit per Day=60

(E ) Predone (prednisolone)-Cipla-1 unit per Day=30

Kidpred-Nicolus -2 unit per Day=60

Omnacortil-macileod -5 unit per Day=150

Neword-P-mankind -2 unit per Day=60


INTEGRAL UNIVERSITY

TO STUDY THE MARKET SHARE OfANTIBIOTIC

Name of medical store: Shive Shakti Medical Store

Name of Doctor Dr. V.K. Kharat

timing : 10am to 1 pm & 6 to 9 am

Address Naca Hindola Aishbag Road

Q.A which brand/company antibiotic they are using

A. Ceftriaxone plus Tazobactum (Cipla) X- Prone 250mg (1 unit per day=30 &

500mg one unit per week=4)

1. X-Pzone-Alkem 250mg (two unit per day=2*30=60 & 50mg per week)=

2*4=8

2. X-P250mg switch 1 unit/day= 30,500mg 1 unit/week=4

3. X-P250mg Praxol 2 unit/ day=2*30=60, 500mg 1 unit/week=4

B. EMESET (CIPLA)-1 unit/day=30

1. Onedem-alken-5 unit/day= 5*30=150

2. vomikiaind-Mankind-1 unit/day=30

3. Ondomac-Maclods- 1 Unit/day=30

4. Emigo-Zuentus-1 Units/day=30

C. Biozora (pre&probiotic)-cipla-1unit per Day=30

Darolac-aristo-6 unit/day=6*30=180

Eubioz-Lupin-1 unit per Day=30


INTEGRAL UNIVERSITY Bifilac-tabletindia-2 unit per Day=2*30=60

Flora-SB-Mankind-2 unit per Day=2*30=60

D. Nitazd (Nitazoxauide) – Cipla- 1 unit per Day=30

Nizonid-Lufin-5 unit per =5*30=150

Zoxakind-mankind-2 unit per Day=2*30=60

Netacur- alembic-1 unit per Day=30

E. Predone (Prednisolone)-Cipla-1 unit per Day=30

Kinpred-Nicolus-2 unit per Day=2*30=60

Omnacortil-macileod-7 unit per Day=30*7=210

Neword-P-mankind-1 unit per Day=1*30=30


INTEGRAL UNIVERSITY


Name of Medical store : S.M. Medical store

Name of Doctor : Dr. Navneet Goal

Timing: 10am to 1 pm & 6 to 9 am.

Address/location : Munsipulia Indira Nagar

Q.A which brand/company they are more preference?

A. Ceftriaxone plus Tazobactum

X-Pzone:(2 unit per day=60, 500mg 1 unit per week=4)-(2 unit per week =8)

alkeme 2) X-P 250 one unit per Day = 30 500mg one unit per week= 4-

switch-3) X-P250mg one unit per Day=30- praxol, 500mg 1unit/week=4

B. EMEST (CIPLA) - 2 unit per day=60

Onedem-alken - 1 unit per day= 30

vomikiaind-Mankind - 2 unit per day=60

Ondomac-Maclods - 1 Unit per day=30

C. Biozora (pre&probiotic) - Cipla-1unit per Day=30

Darolac-Aristo - 2 unit per day=60

Eubioz-Lupin - 1 unit per Day=30

D. Nitazd (Nitazoxauide) - Cipla- 1 unit per Day=30


INTEGRAL UNIVERSITY Nizonid-Lufin - 1 unit per day =30

Nizonid-indswift - 1 unit per day =30

Zoxakind-mankind - 2 unit per Day=60

Netacur- alembic - 1 unit per Day=30

E. Predone (Prednisolone) - Cipla-1 unit per Day=30

Kinpred-Nicolus - 1 unit per Day=30

Omnacortil-macileod - 3 unit per Day=90

Neword-P-mankind - 1 unit per Day=30


INTEGRAL UNIVERSITY


Name of Medical store : Mini Medical store & medico centre & Prem

medicine

Name of Doctor : Dr. Atul Rastogi


Address/location : munsipulia indira nagar

Q.A which brand/company antibiotic they are using?

A. Ceftriaxone plus Tazobactum X-pzone 250mg (2 unit/day=60&500mg one unit

per week=4

X-P250mg alkem ( 2 unit per day=60 & 500mg 2 unit per week=8

X-P250mg switch 2 unit/day=60,500mg 3 unit/week=12

X-P250mg praxol 3 unit/day=90,500mg 1 unit/week=4





Emigo-Zuentus - 4 unit per day=120





INTEGRAL UNIVERSITY Bifilac-tabletindia - 4 unit per day=120

Flora – SB- Mankind - 6 unit per day=180


Nizonid-Lufin - 5 unit per day =150


Netacure- alembic - 6 unit per Day=180






INTEGRAL UNIVERSITY


Name of Medical store : Mini Medical store

Name of Doctor : Dr. Debasheesh shaha


Address : Alambagh kanpur road NAHERIA


A. Ceftriaxone plus Tazobactum X-pzone 250mg

(1 unit/day=30&500mg one unit per week=4




B. EMEST (CIPLA) -1 unit per day=30





C. Biozora (pre&probiotic)-Cipla-1unit per Day=30



Bifilac-tabletindia - 1 unit per day=30


INTEGRAL UNIVERSITY Flora – SB- Mankind - 3 unit per day=90










INTEGRAL UNIVERSITY


Name of Medical store : Mini Medical store

Name of Doctor : Dr. Atul Rastogi


Address : Alambagh Kanpur Road












C. Biozora (pre&probiotic) - Cipla-1unit pe Day=30












Omnacortil-macileod - 3 unit per day=90



INTEGRAL UNIVERSITY


Name of Medical store : Maya Medical store

Name of Doctor : Dr. Devashees Shah


Address : Alambagh Kanpur road

















INTEGRAL UNIVERSITY


Name of Medical store : Gopal Medical store

Name of Doctor : Dr. satish Chandra

Timing: 9am to 12 am

Address : 4,D.A. vcollege, compound, isbhagh l.K.O



(1 unit/day&500mg one unit per week

X-P250mg alkem ( 2 unit per day & 500mg 1 unit per week

X-P250mg switch 1 unit/day,500mg 1 unit/week

X-P250mg praxol 1 unit/day,500mg 1 unit/week

B. EMEST (CIPLA) - 10 unit per day

Onedem-alken - 3 unit per day

vomikiaind-Mankind - 2 unit per day

Ondomac-Maclods - 2 Unit per day

Emigo-Zuentus - 1 unit per day

C. Biozora (pre&probiotic) - Cipla-2unit pe Day


Eubioz-Lupin - 1 unit per Day

Bifilac-tabletindia - 2 unit per day


INTEGRAL UNIVERSITY Flora – SB- Mankind - 3 unit per day

D. Nitazd (Nitazoxauide) - Cipla- 1 unit per Day

Nizonid-Lufin - 10 unit per day

Zoxakind-mankind - 3 unit per Day

Netacure- alembic - 3 unit per Day

E. Predone (Prednisolone) - Cipla-1 unit per Day

Kinpred-Nicolus - 2 unit per Day

Omnacortil-macileod - 10 unit per day

Neword-P-mankind - 1 unit per Day


INTEGRAL UNIVERSITY


Name of Medical store : Suraj Medical Store

Name of Doctor : Dr. Ajay Kumar

Timing: 8pm to 9pm.

Address : home Mothe chile care centre, alambagh l.K.O


A. Ceftriaxone plus Tazobactum X-

pzone 250mg(2 unit/day=60&500mg 2 unit per week=8

X-P250mg alkem ( 2 unit per day=60 & 500mg 1 unit per week=4)




Onedem-alken - 3 unit per day=90









INTEGRAL UNIVERSITY


Name of Medical store : Rani Medical store

Name of Doctor : Dr. Rajeev singh

Timing: 11pm to 4pm.

Address : opposite Aryan restaurant, Sahu Plaza, Alambagh

L.K.O




X-Pzon250mg alkem ( 2 unit per day=60 & 500mg 2 unit per week=8)












INTEGRAL UNIVERSITY


Name of Medical store : Maya Medical Store

Name of Doctor : Dr. V.B Panday

Timing: 12pm to 3pm.

Address : Amirudaula park near Gulamarg, Hotel Lucknow

















INTEGRAL UNIVERSITY


Name of Medical store : Mohan Medical Store

Name of Doctor : Dr. Manju Agrawal

Timing: 10am to 1pm &6 to 9pm

Address : Maulana Cant Guruchand road sadar bazar


A. Ceftriaxone plus Tazobactum X-pzone 250mg(1 unit/day=30&500mg 1 unit per

week=4














INTEGRAL UNIVERSITY


Name of Medical store : Shiv Shakti Medical store

Name of Doctor : Dr. Jaspal singh

Timing: 10pm to 1pm.& 6 to 9 pm

Address : Nace Hindola Aishbag Road



week=4














INTEGRAL UNIVERSITY


Name of Medical store : Duraha Medical Store & Mahi Medical Store

Name of Doctor : Dr. Navneet goal

Timing: 9am to 12pm.& 6 to 9 pm

Address : Munsipulia Indiranager


A. Ceftriaxone plus Tazobactum X-pzone 250mg(2 unit/day=2*30=60&500mg 1

unit per week=4

X-Pzon250mg alkem ( 2 unit per day=2*30=60 & 500mg 2 unit per

week=8)

X-P250mg switch 2 unit/day=30*2=60,500mg 1 unit/week=4











INTEGRAL UNIVERSITY


Name of Medical store : Mohan Medical store

Name of Doctor : Dr. O.P. Tondon


Address : Pandariba crossing



week=4



X-P250mg praxol 1unit/day=30,500mg 1 unit/week=4

B. EMEST (CIPLA) -2 unit per day=60










INTEGRAL UNIVERSITY


Name of Medical store : Sheel Medical store

Name of Doctor : Dr. Ranjeet Dixit


Address : Maqboolgang, Husangunj


A. Ceftriaxone plus Tazobactum X-pzone 250mg(1 unit/day&500mg 1 unit per

week)

X-Pzon250mg ( 1 unit per day & 500mg 1 unit per week)

X-P250mg switch 1 unit/day,500mg 1 unit/week

X-P250mg praxol 1unit/day,500mg 1 unit/week

B. EMEST (CIPLA) - 2 unit per day

Onedem-alken - 3 unit per day

vomikiaind-Mankind - 1 unit per day

Ondomac-Maclods - 4 Unit per day

Emigo-Zuentus - 1 unit per day

C. Biozora (pre&probiotic) - Cipla-1unit per Day

Darolac-Aristo - 3 unit per day

Eubioz-Lupin - 1 unit per Day

Bifilac-tabletindia - 1 unit per day


INTEGRAL UNIVERSITY Flora – SB- Mankind - 3 unit per day

D. Nitazd (Nitazoxauide) - Cipla- 1 unit per Day

Nizonid-Lufin - 4 unit per day

Zoxakind-mankind - 2 unit per Day

Netacure- alembic - 1 unit per Day

E. Predone (Prednisolone) - Cipla-1 unit per Day

Kinpred-Nicolus - 4 unit per Day

Omnacortil-macileod - 6 unit per day

Neword-P-mankind - 1 unit per Day


INTEGRAL UNIVERSITY


Name of Medical store : Sanjay Medical store

Name of Doctor : Dr. Asheesh Mathura


Address : 4 Kaber Marge Udayagang


A. Ceftriaxone plus Tazobactum X-pzone 250mg (1 unit/day=30&500mg 1 unit per

week=4)


X-P250mg Switch 2 unit/day=60,500mg 3 unit/week=12

X-P250mg Praxol 1unit/day=30,500mg 1 unit/week=4











INTEGRAL UNIVERSITY


Name of Medical store : Shri Ganesh Medical store

Name of Doctor : Dr. O.P. Tonden

Timing: 10am to 1pm. & 6 to 9 pm

Address : Naka Hindola Aishbagh Raod



week=4)

X-Pzon 250mg (2 unit per day=60 & 500mg 1 unit per week=8)






Ondomac-Maclods - 1 unit per day=30








INTEGRAL UNIVERSITY










INTEGRAL UNIVERSITY


Name of Medical store : Standard medical store

Name of Doctor : Dr. O.P. Tondon


Address : Nace Hindola Aishbag Road



week=4)














INTEGRAL UNIVERSITY


Name of Medical store : Shri Ganesh Medical store

Name of Doctor : Dr. O.P. Tonden


Address : Naka Hindola Aishbagh Raod



week=4)














INTEGRAL UNIVERSITY


Name of Medical store : Bala ji medical store

Name of Doctor : Dr. Sandeep Bhattacharaya


Address : lal kua: Husangang



week=4)














INTEGRAL UNIVERSITY


Name of Medical store : Shive Shakti Medical Store

Name of Doctor : Dr. Jaspal Singh


Address : Naka Hindola Aishag Road



week=4)















INTEGRAL UNIVERSITY










INTEGRAL UNIVERSITY


Name of Medical store : Bala Ji Medical Store

Name of Doctor : Dr. A.K. Sawal


Address : Medical College



week=4)














INTEGRAL UNIVERSITY


Name of Medical store : Bharat Medical Store

Name of Doctor : Dr. Mohamed Raeesh Alam


Address : Khurram Nager, Husan Gang



week=4)














INTEGRAL UNIVERSITY

ANALYSIS AND DISCUSSION OF RESEARCH FINDING

At it has been already mentioned that (50) Pediatrician and Chemistry were personally

interacted. It is to be mentioned that pediatrician were found using Antibiotic of different

brand. The Antibiotic is being used by Doctors especially depending on the indication.

The Doctors were further asked regarding use of brand at a time. More than half of the

sample Doctors reported using of single brand (50%). Which one fourth Doctors were

found using two brand at a time while about (30%) Doctors were reported to be using

three brands at a time while about (20%) Doctors found using.

The market size of Antibiotic per month in Lucknow City was reported to be used by

sample Doctors only out of total Antibiotic used by sample Doctors per month.

The highest market share was computed to be EMESET approximately 1500 per

month for the above antibiotic the market share of Ondem Alken is approximately

-1950 per month that are market leader at the movement. They are closely

followed by Vomikind-Mankind – 1860 per month. Other brands holding Minor

share are Ondomac Maclods, Emigo-Guentus.


INTEGRAL UNIVERSITY The second market share was computed to be Darolac-Aristo-2340 per month. For

the above market share of Biozova-Cipla is approximately-960 per month that are

not market leader at the movement. They are closely followed by Eubioz-Lupin

approximately-1020 per month.

The third market share was computed to be Nizonide-Lufin approximately-1860

per month for the above market share of Zoxakind Mankind approximately 1710

per month. This is the big comptitore of Nizonide at the moment.

The fourth market share was computed to be Ommacortil-Macileod

approximately-2850 per month. Which is leed to the other antibiotic? Other

antibiotic is Kidpred-1950 per month, Neword-P- Mankind-1200 per month and

Predone-810 per month.


INTEGRAL UNIVERSITY

BIBLIOGRAPHY

Web Sites

www.google.com

www.cipla.com

www.cipla.co.in

[email protected]


qavi project

Documents